Juan F. O.
- Country
- Ireland
- Department
- Neurology
Research Overview
- Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Trial of Intrathecal Mivelsiran (ALN‑961583) in Adults with Early‑Stage Down Syndrome‑Associated Alzheimer’s Disease
- A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome (ABATE)
- Evaluation of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Early Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Data & Insights
Has run more than one trial at 10 of 50 partner sites.
Specializations
Alzheimer's Disease Research
This investigator specializes in studying early-stage Alzheimer's disease and its progression, with particular focus on anti-tau therapies and cognitive assessment methods. Their research encompasses evaluation of novel therapeutic approaches targeting pathological proteins associated with neurodegeneration.
- Early-stage disease intervention
- Tau protein targeting treatments
- Clinical dementia assessment
The investigator utilizes advanced clinical measures including the Clinical Dementia Rating Scale to track disease progression and treatment outcomes.
Down Syndrome Studies
A significant focus of research involves investigating the relationship between Down Syndrome and Alzheimer's disease, particularly examining neurological markers and risk factors. The investigator studies sleep patterns and circadian rhythms as potential indicators of disease progression.
- Down Syndrome-associated Alzheimer's
- Sleep disorder analysis
- Body temperature monitoring
Their work includes longitudinal assessments using PET imaging techniques to track tau pathology development.
Diagnostic Innovation
The investigator advances diagnostic methodologies through comparative studies of tau PET tracers and novel biomarker development. Their research includes evaluation of imaging technologies and pharmacodynamic markers for early disease detection.
- PET tracer optimization
- Biomarker validation
- Cognitive assessment tools
They employ multiple diagnostic approaches to enhance early detection and monitoring of neurodegenerative conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.